Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Maddux

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Psychopharmacology Bulletin|July 15, 2003
Long-term antidepressant treatmentKatia K Delrahim, Rachel Maddux, Mark Hyman Rapaport
The Journal of Allergy and Clinical Immunology|October 9, 2025
Cendakimab (anti-IL-13) administration improves esophageal gene expression in eosinophilic esophagitisJulie M Caldwell, Adina Y Ballaban, Jie Li, et al.
Psychotherapy and Psychosomatics|August 22, 2008
Clinical features and functioning of patients with minor depressionRobert H Howland, Pamela J Schettler, Mark Hyman Rapaport, et al.
Digestive Diseases and Sciences|April 3, 2024
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's DiseaseSarah Harris, Brian G Feagan, Stephen Hanauer, et al.
European Journal of Neurology|June 4, 2025
Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod TrialsSarah Harris, Giancarlo Comi, Bruce A C Cree, et al.
Annals of Clinical and Translational Neurology|August 8, 2023
SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosisBruce A C Cree, Rachel Maddux, Amit Bar-Or, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Psychopharmacology Bulletin|July 15, 2003
Long-term antidepressant treatmentKatia K Delrahim, Rachel Maddux, Mark Hyman Rapaport
The Journal of Allergy and Clinical Immunology|October 9, 2025
Cendakimab (anti-IL-13) administration improves esophageal gene expression in eosinophilic esophagitisJulie M Caldwell, Adina Y Ballaban, Jie Li, et al.
Psychotherapy and Psychosomatics|August 22, 2008
Clinical features and functioning of patients with minor depressionRobert H Howland, Pamela J Schettler, Mark Hyman Rapaport, et al.
Digestive Diseases and Sciences|April 3, 2024
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's DiseaseSarah Harris, Brian G Feagan, Stephen Hanauer, et al.
European Journal of Neurology|June 4, 2025
Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod TrialsSarah Harris, Giancarlo Comi, Bruce A C Cree, et al.
Annals of Clinical and Translational Neurology|August 8, 2023
SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosisBruce A C Cree, Rachel Maddux, Amit Bar-Or, et al.
Pageof 1